(1) Background: Prostate-specific membrane antigen (PSMA) has been extensively studied in the last decade. It became a promising biological target in the diagnosis and therapy of PSMA-expressing cancer diseases. Although there are several radiolabeled PSMA inhibitors available, the search for new compounds with improved pharmacokinetic properties and simplified synthesis is still ongoing. In this study, we developed PSMA ligands with two different hybrid chelators and a modified linker. Both compounds have displayed a promising pharmacokinetic profile. (2) Methods: DATA5m.SA.KuE and AAZTA5.SA.KuE were synthesized. DATA5m.SA.KuE was labeled with gallium-68 and radiochemical yields of various amounts of precursor at different temperatures wer...
In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have beco...
Prostate-specific membrane antigen (PSMA)-targeted radioligands have been used for the treatment of ...
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains challenging with cu...
Since prostate-specific membrane antigen (PSMA) has been identified as a diagnostic target for prost...
The prostate-specific membrane antigen (PSMA)-targeted radiotracers Ga-68/Lu-177-PSMA-I&T and Tc...
Prostate-specific membrane antigen (PSMA) is overexpressed in the majority of prostate cancer cells ...
Abstract Background The target...
We radiolabeled a ligand, PSMA-617, of prostate-specific membrane antigen (PSMA) with copper-64 (64C...
Background: The rising incidence rate of prostate cancer (PCa) has promoted the development of new d...
Prostate cancer surgery is currently being revolutionized by the use of prostate-specific membrane a...
Objectives: PSMA is a well-recognized target for imaging and therapy of prostate cancer (PCa), as it...
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a...
<bold>Introduction:</bold> Prostate specific membrane antigen (PSMA), highly expressed i...
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and thera...
Background The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest...
In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have beco...
Prostate-specific membrane antigen (PSMA)-targeted radioligands have been used for the treatment of ...
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains challenging with cu...
Since prostate-specific membrane antigen (PSMA) has been identified as a diagnostic target for prost...
The prostate-specific membrane antigen (PSMA)-targeted radiotracers Ga-68/Lu-177-PSMA-I&T and Tc...
Prostate-specific membrane antigen (PSMA) is overexpressed in the majority of prostate cancer cells ...
Abstract Background The target...
We radiolabeled a ligand, PSMA-617, of prostate-specific membrane antigen (PSMA) with copper-64 (64C...
Background: The rising incidence rate of prostate cancer (PCa) has promoted the development of new d...
Prostate cancer surgery is currently being revolutionized by the use of prostate-specific membrane a...
Objectives: PSMA is a well-recognized target for imaging and therapy of prostate cancer (PCa), as it...
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a...
<bold>Introduction:</bold> Prostate specific membrane antigen (PSMA), highly expressed i...
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and thera...
Background The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest...
In recent years, a number of drugs targeting the prostate-specific membrane antigen (PSMA) have beco...
Prostate-specific membrane antigen (PSMA)-targeted radioligands have been used for the treatment of ...
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains challenging with cu...